Treats uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae…. ANDA 201691, held by Alkaloida Zrt. Hydroxychloroquine Sulfate.
As of Nov 15, 2026, ANDA 201691 (Hydroxychloroquine Sulfate), held by Alkaloida Zrt, was first approved by FDA on May 8, 2018, with 3 approved supplements and 0 published complete response letters.
Hydroxychloroquine sulfate tablets are antimalarial and antirheumatic indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 8, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydroxychloroquine Sulfate200MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Aug 27, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 5, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 14, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 8, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters